Evidence map›Paper›PMID 26518771›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas.

Kerstin Wenzl, Sybille Hofer, Katharina Troppan, Markus Lassnig, Elisabeth Steinbauer, Marco Wiltgen, Barbara Zulus, Wilfried Renner, Christine Beham-Schmid, Peter Neumeister and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Kerstin WenzlDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria.
Sybille HoferDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria.
Katharina TroppanDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria.
Markus LassnigDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria.
Elisabeth SteinbauerInstitute of Pathology, Medical University of Graz Austria, Graz, Austria.
Marco WiltgenInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz Austria, Graz, Austria.
Barbara ZulusDivision of Medical and Chemical Laboratory Diagnostics, Medical University of Graz Austria, Graz, Austria.
Wilfried RennerDivision of Medical and Chemical Laboratory Diagnostics, Medical University of Graz Austria, Graz, Austria.
Christine Beham-SchmidInstitute of Pathology, Medical University of Graz Austria, Graz, Austria.
Peter NeumeisterDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria.
Alexander DeutschDivision of Hematology, Department of Internal Medicine, Medical University of Graz Austria, Graz, Austria. alexander.deutsch@medunigraz.at.
Medical University of Graz · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic alterations causing constitutive activation of the nuclear factor kappa B (NF-κB) signaling pathway has been associated with the development of lymphomas. A20 (TNFAIP3) is a key regulator of NF-κB signaling. Its suppressor functions are often inactivated by deletions and/or mutations in various hematologic malignancies. Since we recently found the rs143002189 polymorphism in the A20 loci in our multiple myeloma samples, we further investigated this polymorphism in different lymphoid neoplasias. For this purpose, we tested 479 cases of the most common B cell malignancies for the presence of the rs143002189 polymorphism. We found a significant higher occurrence of the rs143002189 polymorphism in diffuse large B cell lymphoma (DLBCL) compared to non-neoplastic controls and other types of B cell malignancies. Furthermore, structure analyses of the mutated A20 protein led to the assumption that the new steric interaction within the protein is responsible for a reduced or inactivated A20 protein. Our data indicates that in a significant fraction of patients, rs143002189 might contribute to the development of DLBCL.

Indexed as

Polymorphism, Single NucleotideCase-Control StudiesGenetic Association StudiesGenetic Predisposition to DiseaseHumansIncidenceLymphoma, Large B-Cell, DiffuseModels, MolecularOpen Reading FramesTumor Necrosis Factor alpha-Induced Protein 3TNFAIP3 protein, humanTumor Necrosis Factor alpha-Induced Protein 3A20DLBCLLymphomaPolymorphism

Identifiers

PMID26518771
OpenAlexW1926090812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.